Diaceutics Plc (GB:DXRX) has released an update.
Diaceutics PLC, a prominent provider of technology and solutions for the pharma and biotech industry, has announced increasing its enterprise-wide engagements to six with top global pharma customers. These engagements, which now contribute £9.0 million to the company’s Annual Recurring Revenue, underscore Diaceutics’ growing importance as a primary commercialisation partner for precision medicines. The company’s largest enterprise-wide customer also extended their contract until the end of 2026, indicating sustained trust and partnership.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.
